Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. 14 October 2020. Gerard von Hoffmann.

Executive Summary

Companies entering clinical trials may be in the worst position to ride out COVID-19, says Gerard von Hoffmann, partner, Knobbe Martens. Here’s why he isn’t sure taking trials overseas is a solution.

“I have seen a couple of companies just step up their efforts to find a jurisdiction outside of the United States to conduct trials on technologies that they did not feel would be considered essential services, at least for some period of time. But the problem is it takes so long and the regulatory effort is so extreme, I'm not sure there's a lot of shortcuts.” – Gerard von Hoffman, partner, Knobbe Martens

Click here for a free trial of Medtech Insight

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts